Trial Profile
Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs RiMO-301 (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Coordination Pharmaceuticals; RiMO Therapeutics
- 06 Jun 2023 Results (n=25) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 09 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 09 Feb 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.